Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MZE829 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| MZE829 | EXPERIMENTAL | Cohort 1: Chronic kidney disease with concurrent diabetes Cohort 2: Chronic kidney disease without concurrent diabetes |
| Name | Type | Description |
|---|---|---|
| MZE829 | DRUG | Capsules for oral administration |
Key Inclusion Criteria: * APOL1 high risk genotype of G1/G1, G2/G2, or G1/G2 * Chronic kidney disease with persistent albuminuria Key Exclusion Criteria: * Organ or bone marrow transplantation * History of active cancer within past 2 years, except for treated non-melanoma skin cancer, stage 0 cer...
MZE829 is an investigational small molecule being developed for the treatment of proteinuric kidney disease, specifically in adults with APOL1 kidney disease. It is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
MZE829 is being developed by Maze Therapeutics, Inc., a biopharmaceutical company. The company is publicly traded under the ticker symbol MAZE.
MZE829 is currently in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The ongoing Phase 2 trial is actively recruiting participants.
MZE829 is being studied in a Phase 2 clinical trial with the identifier NCT06830629. This trial is titled 'A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease' and is recruiting participants in the United States, France, and the United Kingdom.
MZE829 is a small molecule designed to treat proteinuric kidney disease. The specific molecular target of MZE829 has not been disclosed in available information, so its precise mechanism of action is not publicly detailed.